Clinical trial
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
NCT05882045 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 30, 2023
- Completion date
- May 14, 2026
- Enrollment
- 1,946 (actual)
- Sites
- 169
Conditions
As the registry lists them; a condition with its own page is linked.